Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

High throughput camelid antibody screening as a drug discovery platform

Award Number: R44GM106519
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/10/2014
PERIOD OF PERFORMANCE END DATE: 08/31/2019

Group Awards By:

View Award Description

High throughput camelid antibody screening as a drug discovery platform - DESCRIPTION (provided by applicant): Monoclonal antibodies are used for treatment of a wide range of diseases from cancer to infectious diseases. However, development of antibodies with high affinity and specificity is still time- consuming, labor-intensive and unpredictable, especially to low immunogenic or toxic targets. A new approach for rapid development of antibodies against a variety of diseases, especially against emerging diseases is much needed. Abzyme Therapeutics LLC is actively developing animal-free antibody discovery platforms to accelerate generation of diagnostic and therapeutic antibodies. Phase I objectives have been successfully completed. Specifically, we have created a so-called yeast surface display camelid Self-Diversifying VHH Antibody Library or SDALib as a monoclonal antibody generating system providing a diverse array of antibodies in vitro, without using in vivo immunization. The main feature of the system is the ability to self-generate a library with diversified antibodies by mean of hypermutation induction in antibody encoding genes. As proof-of-principle, we have successfully used the platform to isolate a set of single-domain antibodies against N1 neuraminidase (NA) derived from influenza H5N1 virus. Obtained VHH antibodies have been shown to express efficiently in a bacterial system providing an opportunity for accelerated scale-up of antibody production for therapeutic application. Anti-NA VHH antibodies have been purified and characterized in in vitro assays. As proof of principle one (Flu27-8) out of several anti-NA VHH antibodies, that is reactive with N1 NAs of both H5N1 and H1N1 influenza viruses, has been humanized preserving the full anti-NA activity of the parental molecule. Bi- valent anti-NA antibodies that have been produced in a bacterial system as linear fusions showed a significant increase in antibody activity in in vitro assays. Subsequent efforts of Phase II consis of three specific aims that will be performed simultaneously: (i) advance the N1 anti-NA antibodies isolated in Phase I toward clinical application by demonstrating both in vitro and in vivo activity against H5N1 and H1N1 influenza viruses; (ii) expand the application of the platform for developing antibodies targeting both hemagglutinin and NAs of other influenza virus subtypes, e.g. H3N2 and H7N9 which have unusual zoonotic potential and aiming for antibodies cross-reacting with several different neuraminidases (H5N1, H1N1, H3N2 and H7N9); (iii) utilize the antibody discovery platform for developing VHH antibodies against a set of cancer targets followed by production of novel IgG-like VHH-based bispecific humanized antibodies. Phase II efforts are to further extend the application of the technology for rapid development of novel antibodies to therapeutic targets and to advance humanized anti-influenza antibodies isolated in phase I into clinical studies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2017	ABZYME THERAPEUTICS, LLC	321 JONES BLVD, STE 300	POTTSTOWN	PA	19464	MONTGOMERY	USA	Biomedical Research and Research Training	000	3	2/8/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $170,345 )
2018	2018	ABZYME THERAPEUTICS, LLC	321 JONES BLVD, STE 300	POTTSTOWN	PA	19464	MONTGOMERY	USA	Biomedical Research and Research Training	000	3	8/23/2018	SUPPLEMENT FOR EXPANSION	$170,345
														Subtotal = $170,345

Issue Date FY: 2017 ( Subtotal = $749,787 )
2017	2017	ABZYME THERAPEUTICS, LLC	321 JONES BLVD, STE 300	POTTSTOWN	PA	19464	MONTGOMERY	USA	Biomedical Research and Research Training	000	3	8/23/2017	NON-COMPETING CONTINUATION	$749,787
														Subtotal = $749,787

Issue Date FY: 2016 ( Subtotal = $750,213 )
2016	2016	ABZYME THERAPEUTICS LLC	271 GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Biomedical Research and Research Training	000	2	8/24/2016	COMPETING CONTINUATION	$750,213
														Subtotal = $750,213

Grand Total All Awards = $1,670,345

Top

All Categories

About

Search

Reports

Data Submission

Award Information

High throughput camelid antibody screening as a drug discovery platform

Award Number: R44GM106519

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/10/2014

PERIOD OF PERFORMANCE END DATE: 08/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer